U.S reaches a deal with Moderna for 100 million doses of potential coronavirus vaccine

U.S. government will buy 100 million doses of Moderna’s experimental COVID-19 vaccine, which is currently in late-stage human trials.

Moderna separately said the deal for its vaccine, mRNA-1273, is worth $1.53 billion and will give the federal government the option to purchase up to 400 million additional doses.

The U.S. has already invested $955 million in Moderna’s vaccine development, bringing its total investment up to $2.48 billion, the company said in a press release Tuesday.

Moderna’s coronavirus vaccine is in late-stage human trials, which will test its efficacy and safety in 30,000 people. The Massachusetts-based company previously said it could expect results as early as October.